March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Subgroup Efficacy Analyses of the VIEW 1 and VIEW 2 Studies of Intravitreal Aflibercept Injection and Ranibizumab for Treatment of Neovascular AMD
Author Affiliations & Notes
  • Allen C. Ho
    Retina, Mid Atlantic Retina, Wills Eye Institute, Philadelphia, Pennsylvania
  • Desmond Thompson
    Regeneron, Tarrytown, New York
  • Robert Vitti
    Regeneron, Tarrytown, New York
  • Yuhwen Soo
    Regeneron, Tarrytown, New York
  • Alyson J. Berliner
    Ophthalmology, Regeneron, New York, New York
  • Georg Groetzbach
    Bayer HealthCare, Berlin, Germany
  • Majid Anderesi
    Bayer HealthCare, Wuppertal, Germany
  • Rupert Sandbrink
    Bayer HealthCare, Berlin, Germany
  • Victor Chong
    Ophthalmology, Oxford Eye Hospital, Oxford, United Kingdom
  • Ursula Schmidt-Erfurth
    Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships  Allen C. Ho, Regeneron (C); Desmond Thompson, Regeneron (E); Robert Vitti, Regeneron (E); Yuhwen Soo, Regeneron (E); Alyson J. Berliner, Regeneron (E); Georg Groetzbach, Bayer HealthCare (E); Majid Anderesi, Bayer HealthCare (E); Rupert Sandbrink, Bayer HealthCare (E); Victor Chong, Bayer HealthCare (C); Ursula Schmidt-Erfurth, Bayer HealthCare (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 3678. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Allen C. Ho, Desmond Thompson, Robert Vitti, Yuhwen Soo, Alyson J. Berliner, Georg Groetzbach, Majid Anderesi, Rupert Sandbrink, Victor Chong, Ursula Schmidt-Erfurth; Subgroup Efficacy Analyses of the VIEW 1 and VIEW 2 Studies of Intravitreal Aflibercept Injection and Ranibizumab for Treatment of Neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3678.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To determine the consistency of efficacy of intravitreal aflibercept injection (IAI; also referred to as VEGF Trap-Eye) across patient subgroups and ranibizumab (RBZ) for 1 year.


A total of 2457 patients were randomized to RBZ 0.5 mg every month (Rq4wk), IAI 2 mg every month (2q4wk), 0.5 mg every month (0.5q4wk), or 2 mg every 2 months (2q8wk) following 3 initial monthly doses. In this subanalysis, proportions of patients losing <15 letters (proportion maintaining visual acuity) and mean change in best-corrected visual acuity (BCVA) at Week 52 were compared across subgroups based on patients' age, baseline visual acuity (VA) and baseline choroidal neovascularization (CNV) lesion size. The Breslow-Day test was used to assess homogeneity.


At baseline, all treatment subgroups were balanced with respect to age, BCVA, and CNV lesion size. At Week 52 across all subgroups, 93% to 100% of patients lost <15 letters on the ETDRS chart and the mean change in BCVA ranged from 6 to 16 letters. At Week 52, all IAI subgroups showed consistent proportions compared with RBZ (Table).


Proportion of patients losing <15 letters and the mean changes in BCVA were consistent across the pre-specified subgroups as defined by age, baseline BCVA and CNV lesion size. Further, VA improved for all intravitreal aflibercept injection subgroups, including the 2q8wk group, and was similar to monthly ranibizumab.  

Clinical Trial: NCT00509795

Keywords: neovascularization • vascular endothelial growth factor • visual acuity 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.